文献速递脑血管病

大动脉粥样硬化性卒中双联与单联抗血小板治疗比较

Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
PubMed 文献 · Stroke · 2019-01-01

基于韩国多中心卒中登记数据库,分析5934例症状性大动脉粥样硬化性闭塞病患者,比较氯吡格雷联合阿司匹林与单用阿司匹林的效果。主要终点为1年卒中复发、心肌梗死和全因死亡的复合结局。双联治疗组主要终点发生频率为12%,单用阿司匹林组为14%,按方案分析和实际治疗分析显示双联治疗显著降低主要终点风险,但意向性分析仅边缘显著。

要点

  • 双联抗血小板治疗可能降低主要复合终点,主要归因于全因死亡减少。
  • 双联治疗未显著减少卒中复发。
  • 研究为非随机回顾性观察性研究,结果需谨慎解读。

核心结论

  • 与单用阿司匹林相比,双联抗血小板治疗组主要终点发生频率较低,主要由全因死亡减少解释。
  • 双联治疗未减少卒中复发。
  • 由于为非随机回顾性观察性研究,结果应谨慎解读。

研究设计与样本

  • 多中心卒中登记数据库(韩国卒中临床研究协作组)回顾性分析。
  • 纳入2008年5月至2015年5月因大动脉粥样硬化性闭塞病导致的急性缺血性卒中患者。
  • 比较氯吡格雷联合阿司匹林(n=2903)与单用阿司匹林(n=3031)治疗。
  • 采用意向性治疗、按方案和实际治疗三种方法分析,并使用倾向评分和逆概率治疗加权 frail 模型平衡组间差异。

主要发现

  • 主要终点(1年卒中复发、心肌梗死和全因死亡的复合结局)在氯吡格雷-阿司匹林组发生频率为12%(n=353),阿司匹林组为14%(n=410)。
  • 按方案分析:风险比0.71(95%CI 0.57-0.88;P=0.002)。
  • 实际治疗分析:风险比0.81(95%CI 0.69-0.96;P=0.02)。
  • 意向性治疗分析:风险比0.86(95%CI 0.74-1.01;P=0.06),仅边缘显著。
  • 双联治疗在所有分析中对全因死亡有益,但未减少卒中复发。

临床怎么用

  • 对于症状性大动脉粥样硬化性闭塞病导致的急性缺血性卒中患者,双联抗血小板治疗可能降低主要复合终点,但需注意研究局限性。
  • 临床决策应结合患者个体情况,并考虑双联治疗未显著减少卒中复发且增加出血风险的可能性(原文未报告出血数据)。

局限性

  • 非随机、回顾性、观察性研究设计。
  • 结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Two large-scale randomized controlled trials of recurrent stroke prevention suggest that dual antiplatelet therapy with clopidogrel plus aspirin is beneficial for prevention of subsequent ischemic events. There is a paucity of data, however, on the efficacy or effectiveness of such an approach in the treatment of stroke patients with symptomatic large artery atherosclerotic occlusive disease. Methods- We used a multicenter stroke registry database (Clinical Research Collaboration for Stroke in Korea) to analyze acute ischemic stroke patients due to large artery atherosclerotic occlusive disease who were treated with aspirin alone or combination of clopidogrel and aspirin from May 2008 to May 2015. The results were analyzed by intention-to-treat, per-protocol, and as-treated methodologies. The primary end point was the 1-year composite outcome of stroke recurrence, myocardial infarction, and all-cause death. To balance the differences between groups, a frailty model using propensity scores and inverse probability of treatment weighting was used. Results- A total of 5934 patients with symptomatic large artery atherosclerotic occlusive disease were treated either with clopidogrel plus aspirin (n=2903, 49%) or aspirin (n=3031, 51%). The frequency of the primary outcome was 12% (n=353) in the clopidogrel-aspirin group and 14% (n=410) in the aspirin group. The hazards of the primary outcome with combination over aspirin only were significantly reduced in the per-protocol and as-treated analyses (hazard ratio, 0.71; 95% CI, 0.57-0.88; P=0.002 and hazard ratio, 0.81; 95% CI, 0.69-0.96; P=0.02, respectively), but there was borderline significance in the intention-to-treat analysis (hazard ratio, 0.86; 95% CI, 0.74-1.01; P=0.06). Combination therapy was beneficial for all-cause death in all analyses but did not reduce recurrent stroke. Conclusions- Compared with patients receiving aspirin monotherapy, the primary outcome seemed to occur less frequently in patients receiving dual antiplatelet therapy, which is explained mainly by the decrease of all-cause death. Since this is a nonrandomized, retrospective, observational study, our study should be cautiously interpreted.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kim D, Park JM, Kang K, et al. Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke. Stroke. 2019. PMID: 30932785. doi:10.1161/STROKEAHA.119.024786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。